KPAP™ sleep therapy platform is designed to enable a more comfortable, adaptive, and patient-centered alternative to traditional continuous positive airway pressure (CPAP) therapy

SleepRes, Inc., a sleep technology company focused on reimagining therapy for sleep breathing disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Kricket PAP device, powered by Kairos Positive Airway Pressure (KPAP)™ for the treatment of obstructive sleep apnea (OSA) in patients weighing more than 66 lbs. The SleepRes PAP system is intended for home, hospital/institutional, and sleep center settings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217300724/en/

The Kricket™ PAP device, powered by Kairos Positive Airway Pressure (KPAP)™

The Kricket PAP device features proprietary KPAP™ technology, designed to dynamically adapt pressure delivery throughout the breathing cycle, rather than maintaining a constant, fixed pressure like traditional CPAP devices. By synchronizing therapy with a patient’s natural respiration and airway dynamics, KPAP™ aims to reduce unnecessary pressure, which may minimize discomfort, alleviate common side effects, and improve tolerance during sleep. The device includes the KPAP™ algorithm, as well as traditional CPAP and automatic PAP therapy modes.

“This milestone marks an important moment for the field of sleep medicine,” said David White, M.D., Harvard Medical School, and chief medical officer of SleepRes. “Kricket opens the door to a new category of positive airway pressure therapy that prioritizes comfort, the patient's ability to adapt, and real-world use, while still delivering the therapy patients need. That balance is critical if we want to meaningfully improve long-term outcomes for people living with obstructive sleep apnea.”

Obstructive sleep apnea affects up to 60 million adults in the U.S.,¹ and is associated with serious health consequences such as cardiovascular disease, diabetes, stroke, depression, and increased risk of motor vehicle accidents. CPAP therapy has been the standard of care for decades, but long-term adherence remains low due to pressure and mask-related issues. Consequently, untreated OSA is pervasive. KPAP™ technology was designed to address the discomfort associated with CPAP therapy with an innovative approach to air pressure delivery that emulates human breathing for a more natural feel.

“Today completes a 4+ year pursuit to provide my own patients with technology designed to emulate natural breathing and address the discomfort and pressure intolerance common with traditional CPAP,” said William H. Noah, M.D., founder of SleepRes and inventor of KPAP™. “Today also begins a new era of PAP therapy and a new hope not only for my patients but patients across the U.S., especially those beginning PAP or those who have previously tried and failed.”

SleepRes plans to commercially launch Kricket in the first half of 2026. The company is actively preparing to scale manufacturing, developing clinical partnerships, and providing education on KPAP™ ahead of launch.

“FDA clearance of Kricket marks a pivotal moment for patient care in sleep medicine,” said John Lipman, CEO of SleepRes. “It validates the innovation behind our technology and moves us another step closer to our mission of improving outcomes for people living with sleep apnea.”

About SleepRes, Inc.

SleepRes is a sleep and respiratory health technology company dedicated to transforming the treatment of obstructive sleep apnea through thoughtful design, advanced engineering, and patient-first innovation. Powered by its proprietary KPAP™ technology, Kricket™ is building a new generation of sleep therapy solutions that prioritize comfort, adherence, and long-term health outcomes.

For more information, visit www.kricket.com.

1. Boers et al. “Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study.” The Lancet Respiratory Medicine, vol. 13, no. 12, 2025, pp. 1078–1086.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251217300724/en/